Alfredson Håkan, Ohberg Lars, Zeisig Ewa, Lorentzon Ronny
Department of Surgical and Perioperative Science Sports Medicine, Sports Medicine Unit, University of Umeå, 901 87 Umeå, Sweden.
Knee Surg Sports Traumatol Arthrosc. 2007 Dec;15(12):1504-9. doi: 10.1007/s00167-007-0415-8. Epub 2007 Sep 18.
Sclerosing polidocanol injections targeting the area with vasculo/neural ingrowth on the ventral side of the tendon have previously been demonstrated to give good clinical results in patients with chronic painful midportion Achilles tendinosis. In this study, 20 consecutive patients (9 men and 11 women, mean age 46 years) with chronic painful midportion Achilles tendinosis were treated with either sclerosing polidocanol injections (Group A) or open surgical revision of the area with vasculo/neural ingrowth on the ventral side of the Achilles tendon (Group B). Before treatment, all patients had structural tendon changes and increased blood flow-neovascularisation demonstrated with US and colour Doppler. Under US and colour Doppler-guidance, both the injections and the surgical revision targeted the area with neovessels just outside the ventral part of the tendon. A maximum of two sclerosing injection treatments, with 6-8 weeks in-between, were given. For evaluation, the patients recorded the severity of Achilles tendon pain during tendon loading activity (their recreational or sport activity), before and after treatment, on a VAS. Patient global satisfaction with treatment was also assessed. At the 3 months follow-up 6/9 (one patient was excluded) patients in Group A, and 8/10 patients in Group B, were satisfied with the treatment and had a significantly reduced level of tendon pain (Group A VAS from 76 to 24, P < 0.05, Group B VAS from 75 to 21, P < 0.05). There was one deep infection in Group B. At the 6 months follow-up, 6/9 patients in Group A, and 10/10 patients in Group B were satisfied. In summary, both treatment with sclerosing polidocanol injections and open surgical revision outside the ventral Achilles midportion show promising short-term clinical results.
先前已证明,针对肌腱腹侧血管/神经长入区域注射硬化聚多卡醇,对于慢性疼痛性跟腱中段肌腱病患者可产生良好的临床效果。在本研究中,20例连续的慢性疼痛性跟腱中段肌腱病患者(9例男性和11例女性,平均年龄46岁),接受了硬化聚多卡醇注射治疗(A组)或对跟腱腹侧血管/神经长入区域进行开放性手术翻修(B组)。治疗前,所有患者均通过超声和彩色多普勒检查显示有肌腱结构改变以及血流增加——新生血管形成。在超声和彩色多普勒引导下,注射治疗和手术翻修均针对肌腱腹侧外侧的新生血管区域。最多进行两次硬化剂注射治疗,间隔6 - 8周。为进行评估,患者在视觉模拟量表(VAS)上记录治疗前后在肌腱负荷活动(娱乐或体育活动)期间跟腱疼痛的严重程度。还评估了患者对治疗的总体满意度。在3个月的随访中,A组6/9例患者(1例患者被排除)和B组8/10例患者对治疗感到满意,并且肌腱疼痛水平显著降低(A组VAS从76降至24,P < 0.05;B组VAS从75降至21,P < 0.05)。B组有1例深部感染。在6个月的随访中,A组6/9例患者和B组10/10例患者感到满意。总之,硬化聚多卡醇注射治疗和跟腱中段腹侧外侧开放性手术翻修均显示出有前景的短期临床效果。